A SU2C Catalyst® Randomized Phase II Trail of The PD1 Inhibitor Pembrolizumab (Keytruda®) With or Without a Vitamin D Receptor Agonist Paricalcitol (Zemplar®) in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (With No Further Improvement in Their Tumor) - Stand Up To Cancer

Blog

Posted October 11, 2019

A SU2C Catalyst® Randomized Phase II Trail of The PD1 Inhibitor Pembrolizumab (Keytruda®) With or Without a Vitamin D Receptor Agonist Paricalcitol (Zemplar®) in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (With No Further Improvement in Their Tumor)

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.